Prevention and prophylaxis of respiratory syncytial virus in pediatric cardiology: a UK perspective

Robert Mr Tulloh*, Sarah Bury

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

5 Citations (Scopus)


Respiratory syncytial virus (RSV) is a common infection, causing bronchiolitis in over 70% of infants each year and almost all children by the age of 2. It is the leading cause of acute lower respiratory tract infections and admissions to hospital worldwide. Previously healthy infants may have a prolonged cough or wheezing following RSV infection but up to 20% of those with congenital cardiac disease will be hospitalized and have significant morbidity and mortality. For this reason, it is generally recommended that many such infants should receive prophylaxis against RSV infection with palivizumab. This paper reviews the current state of knowledge about RSV affecting children with congenital heart disease from the perspective of those living in the UK and the current protection offered to such children. We also discuss the plans for the future of protection against RSV.

Original languageEnglish
Pages (from-to)235-242
Number of pages8
JournalFuture Cardiology
Issue number2
Publication statusPublished - Mar 2014


  • Congenital heart disease
  • palivizumab
  • prophylaxis
  • pulmonary hypertension
  • respiratory syncytial virus
  • RSV
  • vaccine
  • viral wheeze


Dive into the research topics of 'Prevention and prophylaxis of respiratory syncytial virus in pediatric cardiology: a UK perspective'. Together they form a unique fingerprint.

Cite this